Pfizer beats Q2 estimates, raises revenue outlook low end as non-Covid sales surge

The US pharma giant cut its full-year Covid product revenue forecast to $4 billion, down from $5 billion, while core pipeline strength lifted the lower bound of total guidance.

{{L:By}} Handelsavisen Newsroom · {{L:Automated}} 2026-08-04 11:16 UTC · 1 {{L:min read}} Last updated: 2026-08-04 11:17 UTC

Pfizer reported second-quarter earnings that surpassed analyst expectations on Tuesday, lifting the lower bound of its full-year revenue guidance.

The pharmaceutical giant attributed the stronger-than-anticipated performance to robust demand for its non-Covid product portfolio, signaling a continued shift away from pandemic-era revenue streams.

Despite the positive quarterly beat, Pfizer simultaneously cut its full-year revenue expectation for its Covid products to $4 billion, down from the approximately $5 billion previously projected.

Despite the positive quarterly beat, Pfizer simultaneously cut its full-year revenue expectation for its Covid products to $4 billion, down from the approximately $5 billion previously projected.

This adjustment reflects the normalizing demand for vaccines and treatments as the acute phase of the pandemic recedes, a trend that has weighed on the company's top-line growth for several quarters.

The divergence between the strong core business and the shrinking Covid segment highlights Pfizer's ongoing transition.

Investors are increasingly focused on the durability of sales for its oncology, inflammation, and rare disease franchises, which are now carrying the weight of the company's growth narrative.